This article has been disseminated on behalf of Helus Pharma and may include paid advertising.
Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists for mental health treatments, announced that co-founders Eric So and Paul Glavine have stepped down from their executive and consulting roles while retaining their positions on the company’s board of directors. So previously served as president and executive chairman, while Glavine served as chief growth officer. The company also appointed Mark Lawson as independent chair of the board, effective immediately, and named So chairman emeritus. Lawson, who has served on the board since November 2020, brings more than 20 years of private equity and investment banking experience.
The leadership changes follow the recent appointment of Michael Halstead as CEO and are intended to support the company’s next stage of development. Both co-founders expressed confidence in the current leadership team and will continue supporting Helus Pharma through their board positions. The company remains focused on advancing its HLP003 and HLP004 clinical programs and continues to anticipate reporting topline data from its Phase 3 APPROACH pivotal study of HLP003 for major depressive disorder in the fourth quarter of 2026.
To view the full press release, visit https://ibn.fm/ayQkS
About Helus Pharma
Helus Pharma(TM), the commercial operating name of Cybin Inc., founded in 2019 (the “Company”), is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs – novel serotonergic agonists: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company’s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.
With class leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.
The Company operates in Canada, the United States, the United Kingdom and Ireland. For Company updates and to learn more about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. Helus Pharma(TM) is a trademark of Cybin Corp.
NOTE TO INVESTORS: The latest news and updates relating to HELP are available in the company’s newsroom at https://ibn.fm/HELP
About TinyGems
TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.TinyGems.com
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer
TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com
TinyGems is powered by IBN
